Problematika geriatrickej onkológie nástojčivo vyžaduje riešenie

Mária Wagnerová

Onkologie. 2007:1(1):3  

Blastic transformation of indolent lymphomas

Jan Hudeček

Onkologie. 2007:1(1):7-8  

The blastic transformation of indolent non-Hodgkin lymphoma, the precondition of which is the existence of clonal divergencies in the tumor, appears in 20-40 % of patients. The risk of transformation is directly related to the duration of illness and the survival of patients after transformation generally does not exceed one year. The risk of blastic transformation is high in case of voluminous tumors at the moment of their diagnosis and in case of incomplete remission in first-line treatment. The therapy of aggressive secondary large-cell lymphoma is problematic due to their higher resistance to standard chemotherapy and restricted blood production...

Chemotherapy of hormonally refractory prostatic carcinoma

Jozef Mardiak

Onkologie. 2007:1(1):9-13  

Prostatic carcinoma is one of the most frequent malignant diseases of males. Expectation of increasing incidence of this disease goes together with population growing old. Androgenic deprivation has been first line therapy of metastatic prostate cancer for more than 60 years. Most of the patients with disseminated disease become resistent to hormonal treatment after 2-3 years. Bones and lymphatic nodes are the most frequent site of metastasising. Prostatic carcinoma has been considered to be a chemoresistant disease for long time. Recent positive results change the view for this disease.

Treatment options in multiple myeloma

Elena Tóthová

Onkologie. 2007:1(1):14-17  

Multiple myeloma is characterized by a high degree of resistance to conventional therapy, which results in a low complete remission rate and in limited survival. The fact that high-dose therapy (HDT) can overcome tumor resistance resulting in a complete remission rate ranging from 25 to 50 %, has prompted the use of HDT followed by autologous stem cell rescue as part of the front-line therapy during the last 15 years. The important issue concerning autologous transplantation is how to improve its efficacy. One way would be a tandem approach (double autologous or autologous followed by dose- reduced intensity allogeneis), the other way would consist...

Biological treatment of the small cell lung cancer

Peter Kasan

Onkologie. 2007:1(1):18-20  

Targeted treatment of lung cancer selectively influences intracelullar signaling pathways by affecting on different parts of expressed cell receptors, which play the role in cancer cell proliferation. „Small molecules (gefitinib, erlotinib) cause inhibition of tyrosine-kinase activity of the intracelullar part of EGF receptor (epithelial growth factor receptor) and block signaling pathway (route) of the protoncogene k-ras aiming at proliferation of cancer cell. Gefitinib effectivity in the treatment of non-small cell lung cancer connects with amount of mutations to EGFR at axone 17-21, effectivity of erlotinib vice versa connects with overexpression...

Minimum (minimal) invasive techniques in early colorectal cancer treatment

Peter Slezák

Onkologie. 2007:1(1):21-23  

Minimally invasive non-operating techniques for treatment of early tumors of colon present a convenient approach for the patient. At most times they can be performed on outpatient basis or with minimal hospital stay. They are non-demanding procedures for the patient and can be used even in patients with high surgical risk. These techniques include classical polypectomy and endoscopic mucosal resection. Other methods used include argon plasma coagulation and laser therapy, if available. These techniques are indicated in findings limited to muscularis mucosa. Risk of complication during and after procedure is low. Endoscopic ultrasound is recommended...

Radiotherapy in treatment of tumor´s of unknown primary

Katarína Kóňová

Onkologie. 2007:1(1):24-27  

In the presented article the author describes possibilities of the use of radiotherapy in the treatment tumorous diseases of unknown primary. She discusses mainly the indication of radiotherapy.

Lung cancer in elderly

Mária Wagnerová

Onkologie. 2007:1(1):28-31  

Lung cancer is the leading cause of cancer deaths in Europe and USA. The median age of diagnosis is currently 69 years, however this is gradually increasing with the aging population. Patients over age of 70 represent 40 % of all patients with non-small cell lung cancer. Age alone has not been found to be a significant prognostic factor in many malignancies, including lung cancer with performance status and stage being of greater importance. In lung cancer it is also evident that older patients gain equivalent benefit from cancer therapies as their younger counterparts. Elderly patients are under-treated in all aspects of their disease course from...

Ze zahraničního tisku

Peter Beržinec

Onkologie. 2007:1(1):37  

Exemestan zlepšuje výsledky adjuvantní léčby hormon-dependentního karcinomu mléčné žlázy u postmenopauzálních žen

Jaroslav Němec

Onkologie. 2007:1(1):39  

ZPRÁVA O DNECH DIAGNOSTICKÉ, PREDIKTIVNÍ A EXPERIMENTÁLNÍ ONKOLOGIE

Jiří Drábek

Onkologie. 2007:1(1):31  

VIII. NITRIANSKE DNI NUKLEÁRNEJ MEDICÍNY, 23.-24. NOVEMBER 2006

Andrej Vondrák

Onkologie. 2007:1(1):32  

SPRÁVA Z X. KOŠICKÝCH CHEMOTERAPEUTICKÝCH DNÍ, 23.−24. NOVEMBER 2006

Radovan Barilla

Onkologie. 2007:1(1):33-36  

Test č. 1/2007

Onkologie. 2007:1(1):40-41